Press Release

Genedata and Sophion Bioscience Announce New Genedata Ready-to-Run Partnership

Integration of Sophion QPatch II and Qube 384 instruments with Genedata Screener® enterprise software streamlines molecular testing on ion channels in pharma R&D.

Basel, Switzerland and Ballerup, Denmark—June 09, 2021—Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced Sophion Bioscience, a global leader in automated patch clamp (APC) technology, as a new Genedata Ready-to-Run partner. Sophion joins a continually expanding group of leading technology providers who collaborate with Genedata to offer standardized integrations with the Genedata Biopharma Platform. The deep integration of Sophion QPatch II and Qube 384 APC instruments with Genedata Screener® enables direct capture, remote analysis, and enterprise access to APC data’s highly informative mechanistic and safety aspects of tested molecules.

Ready-to-Run Partners Create Added Value for Their Customers

“The Sophion team is passionate about improving lab efficiency by making patch clamping easy, fast, and accurate. As a Genedata Ready-to-Run partner we will help our joint customers further improve their efficiency and implement innovative screening technologies without investing the time and resources typically required for technology integrations of this nature,” said Thais Johansen, CEO of Sophion Bioscience.

“The combined power of Sophion Analyzer and Genedata Screener will enable advanced electrophysiological analysis and data analysis in a screening context – all on a single platform,” continued Johansen. “This capability will make ion channel testing a routine R&D activity while strengthening our digitalization of drug discovery.”

Ready-to-Run partnerships streamline lab automation to reduce overhead and accelerate drug discovery. Integrating Sophion APC instrumentation with Genedata Screener improves lab efficiency by automating end-to-end data processing; further standardization and de-duplication in global research for increased cost benefits; and yields transparent information for high-quality decisions in research and development projects, allowing researchers to focus on the best molecules to progress. Sophion and Genedata enable a new level of ion channel research in which:

- QPatch II and Qube current and voltage traces are imported directly into Genedata Screener for functional analysis, and are visible on its web clients;
- standardized assay protocols can be shared across different instruments, labs, and sites;
- APC data are analyzed in a screening context, i.e., integrated with molecule and assay property information, scaling from one to hundreds of plates per batch;
• Ion channel analysis results are reported directly to the data warehouse, accessible to the corporate research community; and
• Toxicity results can be compared with results from other assays for a complete overview of compound properties.

“Genedata is continually strengthening our technology portfolio with innovative companies that accelerate novel drug discovery worldwide,” said Dr. Othmar Pfannes, CEO of Genedata. “Therefore, we’re excited to welcome Sophion as a Ready-to-Run partner who will fortify our APC market position and more importantly maximize technology ROI for both Genedata and Sophion customers.”

About Genedata Ready-to-Run
The vendor-agnostic Genedata Biopharma Platform maintains flexible data import APIs, enabling integration with virtually any instrument. Many devices, however, produce highly complex data with massive amounts of data per plate. The Genedata Ready-to-Run program addresses these data acquisition challenges. With the oversight and support of respective instrument companies, Ready-to-Run integrations are instrument-specific, versioned, tested, and maintained by Genedata as part of its standard licensing agreements. The Ready-to-Run program is open to all qualified vendors. Instrument providers interested in joining the program may submit their requests to ready-to-run(at)genedata.com.

About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Trusted by multinational pharmaceutical companies and cutting-edge biotechs around the globe, these solutions digitalize and automate data rich and complex processes to enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

www.genedata.com
LinkedIn | Twitter | YouTube

About Sophion
Sophion was founded almost twenty years ago by a group of passionate electrophysiologists, all having the shared purpose of making patch clamping objective and independent of user skills to provide faster, more accurate, and objective patch clamping results. “To take the voodoo out of patch clamping,” the Sophion product range offers the most flexible automated patch clamp systems on the market today with QPatch and Qube 384.

www.sophion.com
LinkedIn | Twitter

Contact
Allison Kurz
Genedata
Public Relations
Phone: +41 61 511 85 61
pr@genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.